Interview: Eucope On Turning Ten, Defending Orphan Incentives And Securing Market Access For Cell And Gene Therapies
Executive Summary
Ten years on from its inception, the European Confederation of Pharmaceutical Entrepreneurs is focused on defending the incentives system for developing orphan drugs.
You may also be interested in...
More Checks And Balances For Orphan Drugs Needed, Says Germany’s G-BA
The German pricing and reimbursement authority wants better scrutiny of orphan drug designations and incentives for orphan drug development to help address the access problem.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.